AEON AEON
Company Profile ↓Company Overview
AEON (AEON) is a publicly traded company listed on with a market capitalization of $3.51M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 71.3%, reflecting efficient use of shareholder capital.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -193.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -193.37% |
Stock Price Performance
| 1 Year: | -59.89% |
| 6 Months: | -75.21% |
| 3 Months: | -68.65% |
| 1 Month: | -58.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 71.3%.
CONS
- Trading 79.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.95M | 4.32M | 2.53M | 5.50M | 5.94M |
| Operating Income | -200.86K | -398.44K | -450.89K | -389.07K | -427.20K | -9.91M | -13.05M | -13.97M | -283.71M | -74.15M | 153.47M | -4.02M | - | -3.95M | -4.32M | -2.53M | -5.50M | -5.94M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.93M | -4.30M | -2.51M | -5.48M | -5.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.10M | -6.64M | -4.54M | -37.14M | -11.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 6.32M | -4.03M | 5.66M | 2.77M | 1.87M | -10.44M | -17.64M | -15.38M | -297.71M | -118.02M | 164.11M | -6.17M | - | 9.10M | -6.64M | -4.54M | -37.14M | -11.79M |
| Diluted EPS | - | - | - | - | - | -0.08 | -0.13 | -0.11 | -8.01 | -227.87 | 304.00 | -11.24 | 3.75 | 2.28 | -0.60 | -0.39 | - | -0.29 |
| R&D Expense | - | - | - | - | - | 7.48M | 9.21M | 9.03M | 6.39M | 5.73M | 4.44M | 972.00K | - | 825.00K | 1.06M | 597.00K | - | 2.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 36.88M | 48.43M | - | 27.82M | 16.30M |
| Operating Income | -36.88M | -48.43M | - | -27.82M | -16.30M |
| EBITDA | -36.88M | -48.36M | - | -27.73M | -16.22M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -55.64M | -52.56M | - | 42.01M | -39.22M |
| Tax Provision | 0 | 0 | - | 0 | 0 |
| Net Income | -55.64M | -52.56M | - | 42.01M | -39.22M |
| Diluted EPS | -182.12 | -172.03 | - | 72.93 | -3.95 |
| R&D Expense | - | 34.75M | - | 14.18M | 4.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Jan 2023 | Jul 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 81.00K | - | 10.78M | - | - | 6.84M | 3.14M | 5.56M |
| Current Assets | - | - | 9.84M | - | - | 6.22M | 1.59M | 3.40M |
| Cash & Equivalents | - | - | 9.75M | 31.20M | 31.20M | 5.16M | 13.00K | 3.01M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | 59.59K | - | 281.19M | - | - | 159.89M | 31.71M | 60.59M |
| Current Liabilities | 59.59K | - | 82.57M | - | - | 13.05M | 14.15M | 6.90M |
| Long Term Debt | - | 70.76M | 60.43M | - | - | - | 11.69M | 34.60M |
| Total Debt | - | - | 131.79M | - | - | 278.00K | 12.96M | 35.74M |
| Total Equity | 21.41K | - | -287.50M | - | -310.82M | -153.04M | -28.57M | -55.03M |
| Shares Outstanding | - | - | 380.98K | - | - | 516.11K | 555.51K | 12.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -28.43M | -35.58M | -20.29M | -17.31M |
| Investing Cash Flow | -170.00K | -306.00K | 0 | -4.00K |
| Financing Cash Flow | 13.56M | 40.51M | 15.15M | 20.30M |
| Capital Expenditure | -170.00K | -306.00K | - | -4.00K |
| Free Cash Flow | -28.60M | -35.89M | -20.29M | -17.31M |
| Net Change in Cash | -15.04M | 4.62M | -5.14M | 2.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 18.3% | - | -147.0% | 71.3% |
| ROCE % | - | 67.5% | - | 252.8% | 1,219.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AEON
AEON Biopharma Raises About $13.6M Net, Regains Listing Compliance - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd0RIZ0FyMTBfdjhmY0lST1Q3UVg5ZGRXNFJfdlRlb0x1QWZKaWV6cHZ5OVl0aEtjS3BpM2ZJS3JidXNqbVVBTlBVZjl2clY3eGJaTUNQS1hWelBQTjk2MnZfZlkzQlZWVHVYaXJIdzVtRG9MQ0J6UmpjcWI2akMtdnpPendlMDFORzF3OG…
AEON Biopharma Regains NYSE American Compliance After Completing Public Offering - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQTDNTQmM5ZHpzeV93bmVQay15OTBxUTlvMkVid3lFQmxIVWRtc3ZiTGI1ekpTZlU3dDlDZzRRWnlHMHRVel96Q3MzUjcwM2N1T0hjQlFuZkxrZjdfTkJXWE02VXRjV3NJU1RaVVRpdGlWZERWUGFyblBtd1p6c3VDdm1LRjhzZDh2NlBYeU…
Japanese Construction Shares Gain After Deadly Kyushu Earthquake - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPb25keWdUcGd4YzhxVVo0eGJWYVBtX1NFRldGazZkNkZPVGt0WWxmblhaalNCSXZIemgyVWVfanlxcGZqaUhPN3kzd2N3QmcwSmk5ODFDa2d3R3NFeWdpVk1rTnBqeDZ2eHhQVXRoQnJTTW02Rjd5Rk1Jazk5bGJvdnZVSFFkcGdGSVJRU2…
[Stock in Focus] AEON remains range-bound after opening higher; dip-buying observed despite the explosion at AEON MALL Kumamoto being viewed as a negative catalyst. - Moomoo
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNMmdsb0twWF93bXliWXhnbzFQYTluTVhHUmJFelJtLUR1UlpPOTdLN2VJSGQzR1Jxa0pZRDhlYWpIZ1hpTS1rQlNuV1hJY2ZZSVJIUUEyV3ZFcWhBX3JLOWZUUkI3RkR4bndLbFRSUmZxa3BCNnA5N3UwNHZqYzNWcmJZTW1RZ1JST0xYSm…
Will Aeon’s (TSE:8267) Q1 2027 Return To Profitability Reshape Its Investment Narrative? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNQUFHeFlxdDc3Smg3YlA2a1FWQjAxS2x0X0cwMUhIZGI2emRBTklCREd5X1N5MGx1QXhmbnpzTDltWTJMLWthVFR5OElhRjNuSGZyNG1yMzd6X1FNYUlTbVNvZVRvWnFxUXBPQm5fQzFZSWhOMURBVWtiNG1zbXRMbGpZY3kzeEtXR3RaQ3…
AEON|Aeon Biopharma Inc|Price:0.253|Chg%:+0.010 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5LaHBwWWtvb2FBVXRsb1BzUkctYXJXYzdjVnNDTEtILTk2djNELVc0QkJCVmJ1MDNfS0JrNjB0LXFVb1pjdDBRUzVZNVZmUTVnNEQzejhfczJtdw?oc=5" target="_blank">AEON|Aeon Biopharma Inc|Price:0.253|Chg%:+0.0…
AEON — Frequently Asked Questions
What is the current share price of AEON?
As of 2026-08-05 17:25 PDT, AEON trades at $0.29 on NASDAQ/NYSE. Its 52-week range is $0.24 to $1.40.
What is the market capitalisation of AEON?
AEON has a market capitalisation of $3.51M on NASDAQ/NYSE.
What is the P/E ratio of AEON?
AEON trades at a trailing price-to-earnings (P/E) ratio of -0.07. Its price-to-book (P/B) ratio is -0.06.
What is the return on equity (ROE) of AEON?
AEON has a return on equity (ROE) of 71.28%.
Is AEON a good stock to buy?
This page provides a data-driven analysis of AEON, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.